Long- and short-term CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic Alzheimerâ€™s mice by John F. Castro-Alvarez et al.
ORIGINAL RESEARCH ARTICLE
published: 10 September 2014
doi: 10.3389/fnagi.2014.00243
Long- and short-term CDK5 knockdown prevents spatial
memory dysfunction and tau pathology of triple transgenic
Alzheimer’s mice
John F. Castro-Alvarez1, S. Alejandro Uribe-Arias1, Kenneth S. Kosik 2 and Gloria P. Cardona-Gómez1*
1 Cellular and Molecular Neurobiology Area, Neuroscience Group of Antioquia, Faculty of Medicine, University Research Headquarters, University of Antioquia,
Medellín, Colombia
2 Department of Molecular Cellular Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA, USA
Edited by:
George E. Barreto, Pontiﬁcia
Universidad Javeriana, Colombia
Reviewed by:
Nibaldo C. Inestrosa, Pontiﬁcal
Catholic University of Chile, Chile
Christian Gonzalez-Billault,
Universidad de Chile, Chile
*Correspondence:
Gloria P. Cardona-Gómez, Cellular and
Molecular Neurobiology Area,
Neuroscience Group of Antioquia,
Faculty of Medicine, University
Research Headquarters, University of
Antioquia, Calle 62# 52–59, Torre 1,
Piso 4, Laboratorio 412, Medellín,
Antioquia, Colombia
e-mail: patricia.cardonag@udea.edu.co
CDK5 is a member of the cyclin-dependent kinase family with diverse functions in both the
developing and mature nervous system. The inappropriate activation of CDK5 due to the
proteolytic release of the activator fragment p25 from the membrane contributes to the
formation of neuroﬁbrillary tangles and chronic neurodegeneration. At 18 months of age
3xTg-AD mice were sacriﬁced after 1 year (long term) or 3 weeks (short term) of CDK5
knockdown. In long-term animals CDK5 knockdown prevented insoluble Tau formation in
the hippocampi and prevented spatial memory impairment. In short-term animals, CDK5
knockdown showed reduction of CDK5, reversed Tau aggregation, and improved spatial
memory compared to scrambled treated old 3xTg-AD mice. Neither long-term nor short-
term CDK5 knock-down had an effect on old littermates. These ﬁndings further validate
CDK5 as a target for Alzheimer’s disease both as a preventive measure and after the onset
of symptoms.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of dementia
in people over 65 with about 24 million people affected world-
wide (Reitz et al., 2011). AD is characterized by abnormal folding
and aggregation of β-amyloid protein (βA) as amyloid plaques
and hyperphosphorylated Tau as neuroﬁbrillary tangles (NFT).
These proteinopathies cause brain atrophy with marked cogni-
tive impairment as the disease progresses (Querfurth and LaFerla,
2010).
Tau is a microtubule (MT)-associated protein that promotes
MT assembly and stabilizes assembled MTs. These functions are
important in the growth of neurons during development and
in axonal transport in mature neurons (Murphy and Borisy,
1975; Mandelkow and Mandelkow, 2012). The phosphoryla-
tion/dephosphorylation rate of Tau by different kinases and
phosphatases regulatesMT function (Wang et al., 2007). An abnor-
mal increase in Tau phosphorylation is associated with loss of its
function, formation of paired helical ﬁlaments (PHF) and extra-
cellular accumulation in NFT (Grundke-Iqbal et al., 1986; Kosik
et al., 1986; Wang et al., 2007).
Cyclin-dependent kinase 5 (CDK5) is one of several kinases
involved in the phosphorylation of Tau (Paudel et al., 1993;
Noble et al., 2003). Pharmacological inhibition and genetic knock
down of CDK5 have been reported as therapeutic approaches
to the tauopathies (Alvarez et al., 1999; Zheng et al., 2005, 2010;
Piedrahita et al., 2010; Crews et al., 2011), but the impor-
tance of this kinase and its role in neurons requires further
study.
Unlike othermembers of theCDK family, CDK5 is not involved
directly in the cell cycle. It is critical in neurodevelopment and
regulates neuronal functions, such as neuronalmaturation,migra-
tion, neurotransmission and synaptic plasticity (Fu et al., 2005;
Ip and Tsai, 2008). CDK5 is expressed in different tissues, but
its activity is higher in neural tissue due to the presence of
the activators, p35 and p39, that are found predominantly in
the nervous system (Tsai et al., 1994; Zheng et al., 1998). Acti-
vation of calcium-dependent proteases m-calpain or μ-calpain
can cleave p35, generating p25 protein, which induces prolonged
activation (Patrick et al., 1999; Lee et al., 2000). In the setting
of a brain insult, such as head injury, calcium inﬂux occurs
and p35 is cleaved near its membrane attachment site. As a
result CDK5 can diffuse through the cytoplasm and phospho-
rylate inappropriate substrates including Tau (Cruz et al., 2003).
Inappropriate localization of CDK5 can contribute to the for-
mation of NTF by Tau hyperphosphorylation and release from
MTs (Patrick et al., 1999; Cruz et al., 2003; Noble et al., 2003),
thereby inducing the breakdown of axonal transport with result-
ing mitochondrial and lysosomal dysfunction (Wang et al., 2009;
Mandelkow and Mandelkow, 2012). These events represent one
plausible pathway toward the phenotype associated with AD NFTs
and other tauopathies such as Progressive Supranuclear Palsy
(PSP) and Frontotemporal Dementia and Parkinsonism linked
to chromosome 17 (FTDP-17; Lee et al., 2011).
Previously, we designed a microRNA-based short hairpin
(sh-miR) against CDK5, which reduced CDK5 protein levels in
vitro and in vivo. We reported that a reduction in CDK5 levels
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can reverse Tau phosphorylation in vitro and in vivo in wild type
(WT) mice and triple transgenic AD model (3xTg-AD; Piedrahita
et al., 2010). Building on these pre-clinical studies and to estab-
lish the therapeutic efﬁcacy of CDK5 silencing in 3xTg-AD mice,
we determined suitable delivery times to obtain reproducible and
beneﬁcial effects of shCDK5miR therapy using Adeno-Associated
Virus (AAV) vectors. At 1 year and at 3 weeks after 3xTg-AD mice
were injected in CA1, learning and spatial memory was tested in
theMorrisWaterMaze (MWM).We found improvedperformance




RNAi sh-miR sequences for silencing of CDK5 (shCDK5miR)
and scrambled RNA sequence as control (shSCRmiR) were
based on previously published sequences (Chang et al., 2006;
Piedrahita et al., 2010). These sequences were cloned into
human miR-30-based stem loops by polymerase extension of
overlapping DNA oligonucleotides. For cloning of RNAi vec-
tors for AAV production, the following primers were used
for polymerase extension: shCDK5miR, forward primer 5′-
AAAACTCGAGTGAGCGCTGACCAAGCTGCCAGACTATACT-
GTAAAGCCACAGATGGG-3′, and shCDK5miR, reverse primer,
5′-AAAAACTAGTAGGCGTTGACCAAGCTGCCAGACTATAC-
CCATCTGTGGCTTTACAG-3′, or shSCRmiR, forward primer,
5′-AAAACTCGAGTGAGCGCA-CCATCGAACCGTCAGAGTT-
ACTGTAAAGCCACAGATGGG-3′, and shSCRmiR reverse
primer, 5′-AAAAACTAGTAGGCGTACCATCGAACCGTCAGA-
GTTACCC-ATCTGTGGCTTTACAG-3′. These extension prod-
ucts were digested with XhoI and SpeI for directional cloning into
a U6 expression plasmid cut with XhoI and XbaI (Boudreau et al.,
2008).
VIRAL PARTICLE PRODUCTION
The protocol to produce AAV particles utilized large-scale pro-
duction of heterologous proteins by Sf9 insect cells culture for
co-infecting recombinant baculovirus derived from the Auto-
grapha californica nuclear polyhedrosis virus (Urabe et al., 2002).
shCDK5miR and shSCRmiR expression cassettes, driven by the
mouse U6 promoter, were cloned into pAAV.CMV.humanized
Renilla GFP (hrGFP), which contains AAV serotype 2/5 inverted
terminal repeats, and a CMV-hrGFP-simian virus 40 poly(A)
reporter cassette (Urabe et al., 2002; Boudreau et al., 2009). AAV
titers were determined by using quantitative PCR and/or DNA slot
blot analysis. The AAV were dialyzed before use.
ANIMAL PROCEDURES
A total of 36 6-month-old-3xTg-AD, 20 6-month-old-control
mice, 34 18-month-old-3xTg-AD and 20 18-month-old-control
mice (Oddo et al., 2003) from our in-house, speciﬁc pathogen-
free (SPF) colony at the vivarium at SIU, University of
Antioquia, Medellín, Colombia, were kept on a 12:12-h
dark:light cycle and received food and water ad libitum. Ani-
mals were handled according to Colombian standards (law
84/1989 and resolution 8430/1993) and the NIH animal wel-
fare care guidelines (Public Law 99-158, November 20, 1985,
“Animals in Research”). Special care was taken to mini-
mize animal suffering and to reduce the number of animals
used.
Animals were anesthetized [ketamine (5%) and xylazine (2%)
to 50:5 dosage mg/kg] and bilaterally injected with 1 μL of AAV2-
shSCRmiR (shSCRmiR) or AAV2-shCDK5miR (shCDK5miR)
into both hippocampi (bregma coordinateswere –1.7 anteroposte-
rior, 0.8 (right) and –0.8 (left) lateral, and 1.75 mm dorsoventral).
Injections were performed with a 10 μL Hamilton syringe at a rate
of 0.1 μL/min and 5 min elapsed after infusion before withdrawal
of the syringe. Experimental groups were: long-term control mice
(control mice at 6 months old were injected and evaluated 1 year
after injection), aged control mice (control mice at 18 months old
were injected and evaluated 3 weeks later), aged 3xTg-AD mice
treated for a short term (ST-3xTg-AD; mice at 18 months old were
evaluated 3 weeks after injection) and 3xTg-AD mice treated for a
long term (LT-3xTg-AD; mice at 6 months were evaluated 1 year
after injection).
MORRIS WATER MAZE TEST
A white plastic tank consisting of a 1 m diameter and 30 cm height
was ﬁlled with water (22 ± 2◦C) to a depth of 20 cm. The plat-
form (7 cm diameter) was 1.5 cm below the surface of the water
during spatial learning and 1.5 cm above the surface of the water
during the visible session. Extramaze visual cues around the room
remained in a ﬁxed position throughout the experiment. Each
session consisted of four successive trials (30 s inter-trial inter-
val) and each trial began with the mice placed pseudo-randomly
in one of four starting locations. Animals had been trained to
remain 30 s on the platform before the initial trial began. Latency
to reach the platform was evaluated with a visible platform to con-
trol any difference between experimental groups in visual-motor
abilities or motivation. Six to eight hidden training sessions (four
trials per session) were conducted with long-term control, aged
control, ST-3xTg-AD and LT-3xTg-AD mice injected with the
shSCRmiR or shCDK5miR treatment to examine spatial learn-
ing performance. If a mouse did not ﬁnd the platform after a
maximum of 60 s it was gently guided to the platform. Ani-
mals were then given 48 h of retention time and were tested in
a probe trial of spatial reference memory for 60 s without the plat-
form. Latency in reaching the exact platform location and time
spent (s) in quadrants were recorded during the probe trial. An
automated system (Viewpoint, Lyon, France) recorded the mice’s
behavior.
WESTERN BLOTTING
After behavior testing, the animals were sacriﬁced and the hip-
pocampus were dissected, immediately frozen in liquid nitrogen
and stored at –80◦C before use. Samples were lysed on 10 mM
Tris, pH 7.4; 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10%
glycerol, 1% NP40, 1 nM orthovanadate, 5 mM NaF, 1 mM
phenylmethylsulfonyl ﬂuoride and protease inhibitors cocktail
(Sigma-Aldrich; Cardona-Gómez et al., 2004). Proteins were
loaded on 8%, 10%, and 15% Tricine Gel and transferred to
nitrocellulose membranes (GE Healthcare) at 250 mA for 2 h
using an electrophoretic transfer system. The membranes were
incubated overnight at 4◦C with anti-CDK5 (C-8), anti-p35/p25
Frontiers in Aging Neuroscience www.frontiersin.org September 2014 | Volume 6 | Article 243 | 2
Castro-Alvarez et al. CDK5 RNAi prevents memory dysfunction
(Santa Cruz Biotechnology). PHF-1 monoclonal antibody, which
recognizes Tau pSer-396/404 donated by P. Davies (Feinstein Insti-
tute for Medical Research, Manhasset, NY, USA), mouse AT8
(pSer202/pThr205), AT100 (pSer212/pThr214), AT180 (pThr231;
Pierce Biotechnology), total Tau (Tau5; Invitrogen), and mouse
anti-βIII tubulin (Promega). IRDye 800CW goat anti-mouse or
rabbit (LI-COR) and anti-mouse IgG or anti-rabbit IgG peroxi-
dase conjugated (Pierce Biotechnology), were used as secondary
probes. The blots were developed using the Odyssey Infrared
Imaging System or chemiluminescence method (ECL Western
blotting system; GE Healthcare) followed by an exposure to a
radiographic ﬁlm(ECLHyperﬁlm;GEHealthcare). Theﬁlmswere
analyzed using Quantity One, version 4.3.0 (Bio-Rad).
SOLUBLE AND SARKOSYL-INSOLUBLE Tau
Preparations of Sarkosyl insoluble Tau were previously described
(Greenberg and Davies, 1990; DeTure et al., 2002). Brieﬂy, hip-
pocampi from ST-3xTg-AD and LT-3xTg-AD mice were lysed on
10 mM Tris, pH 7.4; 100 mM NaCl, 1 mM EDTA, 1 mM EGTA,
10% glycerol, 1% NP40, 1 nM orthovanadate, 5 mM NaF, 1 mM
phenylmethylsulfonyl ﬂuoride, and protease inhibitors cocktail
(Sigma-Aldrich). Lysates were spun at 13,000 rpm, 4◦C, 10 min,
a fraction of the supernatant was stored as the soluble fraction.
Remaining fraction was diluted in Sarkosyl buffer (50 mM Tris–
HCl, pH 7.4; 0.15 M NaCl, 1% lauryl sarcosine, protease inhibitor
cocktail) and spin at 13,000 rpm, 4◦C, 10 min. The supernatant
was incubated for 30 min/RT and centrifuged at 40,000 rpm/2 h.
The pellet was diluted in Sarkosyl buffer and stored as insolu-
ble fraction. The soluble and insoluble fractions were analyzed
with PHF1 and β-actin (Sigma-Aldrich) monoclonal antibodies
by western blot, as described above.
CDK5 KINASE ASSAY
Hippocampi from ST-3xTg-AD,LT-3xTg-AD, and long-term con-
trol mice were dissected and rapidly frozen in liquid nitrogen
immersion. Brain tissue was thawed on ice and homogenized,
incubated for 15 min on ice, and centrifuged at 13,000 rpm/4◦C.
CDK5 was immunoprecipitated with polyclonal anti-CDK5 (C-8)
antibody. After 24 h of incubation, protein G-Sepharose beads
were resuspended in 200 μL of kinase assay buffer (20 mM Tris–
HCl, pH 7.5, 100 μM sodium orthovanadate, 10 mM MgCl2,
50 mM NaCl, 1 mM DTT, and 1 mM NaF), and ATP was added
to the resuspended beads at a 10-fold excess (0.5 mM). His-
tone from calf thymus type III-S (Sigma-Aldrich) was added
as a substrate for CDK5 at a ﬁnal concentration of 6 μM,
and then the reaction was gently vortexed and incubated at
37◦C for 30 min. Reaction were stopped with 5 μL of load-
ing buffer (250 mM Tris–HCl, 10% SDS, 30% glycerol, 0.5 M
DTT, 0.02% bromophenol blue), immediately followed by 5 min
incubation at 95◦C. Western blotting detection for anti-histone
H1 phosphorylated, CDK5, and IgG were made as described
above.
IMMUNOFLUORESCENCE
Mouse brains were ﬁxed with 4% paraformaldehyde in PBS, cry-
opreserved with 30% sucrose and stored at 20◦C. Brains were
cut in 50 μm coronal sections with a vibratome (Leica 1000)
and treated with 50 mM NH4Cl for 10 min at room tem-
perature. Slices were preincubated 1 h in 1% BSA with 0.3%
Triton X-100 in 0.1 M PB. Primary antibodies were incubated
overnight at 4◦C. We used PHF-1 monoclonal antibody, which
recognizes Tau phospho-Ser-396/404. Secondary antibodies were
conjugated to ﬂuorophore Alexa 594 (Molecular Probes). The
slices were observed by Confocal-DSU microscope Olympus IX-
8 and analyzed as individual images for PHF-1 expression and
GFP as a reporter gene. Deconvolution, maximal projection
and ﬂuorescence intensity were done using Image Scope-Pro
software (Media Cybernetics) and Cell software (Olympus),
respectively.
STATISTICS
At least n = 3–4 mice were used for histological and biochemical
studies from n = 10–18 animals used for behavioral evaluation.
Parametric data was compared using Student’s t-test for contrast
groups. Nonparametric data was evaluated by the Mann–Whitney
U test. Escape latency during the visible and hidden training
was determined by repeated-measures ANOVA with session as a
within-subject factor and treatment (shSCRmiR, shCDK5miR) as
between-subjects factor. In the hidden trials separately and probe
trial used Student’s t-test for latency and two-way ANOVA with
treatment-time in quadrants as between subject factors. SPSS was
used and results were considered signiﬁcant when p ≤ 0.05. Values
were expressed as mean ± SEM.
RESULTS
LONG STANDING PREVENTION OF SPATIAL MEMORY IMPAIRMENT IN
3xTg-AD 1 YEAR AFTER CDK5 KNOCKDOWN
Six-month-old 3xTg-AD mice were injected with either
shCDK5miR or shSCRmiR in CA1 and were evaluated by MWM
test 1 year post-injection. Before cognitive testing all the animals
found the visible platform quickly indicating no visual, motor or
motivational deﬁcits [session effect F(1,34) = 53.245; p < 0.001;
treatment effect F(1,34) = 0.012; p = 0.915; session-treatment
effect F(1,34) = 0.5; p = 0.484; Figure 1A, Visible platform].
In the learning test, shSCRmiR treated mice did not improve
during hidden platform training with respect to shCDK5miR
treated mice [session effect F(7,238) = 11.04; p < 0.001; treat-
ment effect F(1,34) = 1.848; p = 0.183; session-treatment
effect F(7,224) = 1.316; p = 0.243; Figure 1A, Hidden plat-
form]. The performance of shCDK5miR treated mice improved
in the last learning session [session 8 (Mann–Whitney U test;
p = 0.038] compared to the shSCRmiR-injected mice, and thus
the shCDK5miR treated mice achieved a performance similar to
long-term control mice (Figure 3A).
In the probe trial or retention test, the 3xTg-AD mice injected
with shCDK5miR showed a signiﬁcant reduction in the latency to
reach the platform position (Mann–Whitney U test; p = 0.004;
Figure 1A, Probe trial). These results were corroborated by an
analysis of the time spent in quadrants by tracking motion.
shCDK5miR-treated animals showed a signiﬁcantly increased time
spent in searching the platform in the target quadrant (TQ) with
respect to the other quadrants [two-way ANOVA F(1,34) = 5.948;
p = 0.02; Figure 1B] and an increase in the path length in the
platform quadrant (Figure 1C). Thus, CDK5 knockdown can
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FIGURE 1 | Long-term therapy (1 year after injection at 6 months
of age) with shCDK5miR in 3xTg-AD mice prevented the spatial
memory deficit. Therapy with shCDK5miR had a beneﬁcial effect on
spatial memory by MWM testing. (A) Values of latency to reach the
hidden platform during training show signiﬁcant difference in the learning
and probe trial tests at 48 h. This effect was replicated in (B) time spent
in the target quadrant and (C) path plots for the median path length.
(TQ = target quadrant, RQ = Right quadrant, UQ = upper quadrant and
OQ = oppositive quadrant.) Data are presented as mean ± SEM. n = 18
by each group, *p < 0.05, **p < 0.01.
contribute to prevention of spatial learning impairment in aged
3xTg-AD mice.
Control mice from the same line (PS1M146V knock-in) at
6 months of age were injected in CA1 with AAV contain-
ing shCDK5miR or shSCRmiR. All mice were evaluated by
the MWM test 1 year post-injection. Performance with the
visible platform demonstrated no deﬁcits in visual, motor or
motivational functions in the injected animals [session effect
F(1,16) = 26.247; p < 0.001; treatment effect F(1,16) = 0.036;
p = 0.853; session-treatment effect F(1,16) = 0.305; p = 0.589;
Figure 3A, Visible platform]. Both shCDK5miR and shSCRmiR
groups could learn the tasks in the hidden platform training [ses-
sion effect F(7,105) = 12.395; p < 0.001], and there were no
differences searching the location of the hidden platform [treat-
ment effect F(1,15) = 1.901; p = 0.188; session-treatment effect
F(7,105) = 0.799; p = 0.606; Figure 3A, Hidden platform]. 48 h
after the last learning trial was assessed a probe trial (without plat-
form), did not reveal any differences in the latency in reaching
the platform-demarcated area (t(15) = 1.46; p = 0.165) or time
spent in the target quadrant [two-way ANOVA F(3,64) = 8.852;
p = 0.588; Figure 3A (Probe trial), and Figures 3B,C].
REDUCED INSOLUBLE Tau AND HYPERPHOSPHORYLATED Tau IN THE
HIPPOCAMPI OF 3xTg-AD FOLLOWING LONG-TERM CDK5 KNOCKDOWN
To detect a biochemical effect of CDK5 knockdown on hyper-
phosphorylation of Tau, the Tau soluble and sarkosyl-insoluble
fraction were separated in LT-3xTg-AD hippocampi. 6-month-
old 3xTg-AD animals injected with shSCRmiR and sacriﬁced
1 year later showed a PHF1 immunoreactive band in 65 kDa
(pSer-396/404; Greenberg and Davies, 1990; Kimura et al.,
2010), characteristic of hyperphosphorylated Tau in the sol-
uble fraction and in sarkosyl-insoluble fraction (Figure 2A).
This band was not present in shCDK5miR treated animals in
both the sarkosyl-insoluble fraction and in the soluble fraction
(Figure 2A).
CDK5 reduction was veriﬁed after 1 year of treatment in
the shCDK5miR treated mice. CDK5 protein levels were signif-
icantly reduced (31.3% ± 2.7 vs control; p = 0.001; Figure 2B).
Several phosphorylation sites in total lysates were evaluated after
CDK5 reduction. There was a signiﬁcant decrease in the AT8
(pSer202/pThr205; 71.9 ± 9.5% vs control; p = 0.049) and
AT100 (pSer212/pThr214; 69.7 ± 9% vs control; p = 0.039)
immunoreactivities, but AT180 (pThr231) did not achieve sta-
tistical signiﬁcance (75.4 ± 9.1%; p = 0.114; Figure 2B). Total Tau
blotted with Tau5 did not differ between the groups (95 ± 10.5%
vs control; p = 0.34; Figure 2B). PHF1 reactivity was quantiﬁed
by immunoﬂuorescence of CA1 that showed reduced signal in the
severity of Tau pathology in the shCDK5miR group (32.2 ± 8%
vs control; p = 0.001; Figure 2C). Taken together the most promi-
nent effect of CDK5 knockdown is on PHF1 hyperphosphorylated
Tau in the sarkosyl insoluble fraction.
CDK5 activity and its effect on tauopathy can be associated
with the modulation of its activator p35 and p25 cleaved form.
Thus, we evaluated p35/p25 levels and CDK5 activity in our sam-
ples. p35 (78.5 ± 2.7% vs control; p = 0.004) was signiﬁcantly
decreased, but there was no change in p25 (118.9 ± 26.9% vs
control; p = 0.533) after 1 year of treatment with shCDK5miR in
3xTg AD mice and there was no signiﬁcant change in the ratio
p25/p35 (153.8 ± 37.6% vs control; p = 0.2476; Figure 2D).
Also, the capacity of CDK5 to phosphorylate an in vitro sub-
strate such as histone H1 in 3xTg-AD knockdown mice was
not changed after 1 year (82.6 ± 23.2% vs control; p = 0.531;
Figure 2E).
Control mice at 6 months of age injected in CA1 with AAV
containing shCDK5miR or shSCRmiR. One year later, after
MWM testing, animals were sacriﬁced and CDK5 protein lev-
els in hippocampal lysates corroborated the shCDK5miR-induced
reduction. CDK5 was diminished in the hippocampi of aged con-
trol shCDK5miR-treated animals in comparison to shSCRmiR-
treated animals (38.7 ± 7.9% vs control; p = 0.004; Figure 3D).
We immunoblotted Tau to evaluate its phosphorylation state at
the AT8, AT100, AT180, and PHF-1 epitopes. CDK5 silencing
reduced Tau phosphorylation at the AT8 (59.8 ± 5.6% vs con-
trol; p = 0.005), with tendency toward a decrease of AT180
(76.2 ± 23.7% vs control; p = 0.103); but not at the PHF1
(91.1 ± 27.9% vs control; p = 0.771), AT100 (91.1 ± 3.8% vs
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FIGURE 2 | Long-term therapy in 3xTg-AD mice with shCDK5miR can
prevent accumulation of insoluble and hyperphosphorylated Tau.
Long-term therapy prevented insoluble Tau accumulation (64 kDa band) as
measured by (A) sarkosyl-insoluble and soluble Tau evaluated with PHF1
antibody, β-actin was used as loading control. (B) Likewise, long-term
shCDK5miR maintained decreased CDK5 protein levels as well as reduced
AT8 and AT100 in hippocampal lysates of 3xTg-AD mice. Representative blots
are shown. Tubulin was used as loading control. Densitometry quantiﬁcation
was done. n = 3, *p < 0.05, **p < 0.01. (C) PHF1 ﬂuorescence intensity
corroborated that Tau hyperphosphorylation diminished with long-term
therapy of shCDK5miR in CA1 of 3xTg-AD mice. PHF1 in red (Alexa 594)
and GFP in green. Magniﬁcation 60×. Scale bar, 50 μm. n = 3. *p < 0.05,
**p < 0.01. (D) p35 levels remain reduced 1 year after treatment with
shCDK5miR. p25 and p25/p35 ratio was slightly increased but did not achieve
statistical signiﬁcance. Representative blots are shown. Tubulin was used as
loading control. Densitometry quantiﬁcation was done. n = 3, *p < 0.05,
**p < 0.01. (E) CDK5 kinase activity evaluated by histone phosphorylation in
long-term treatment in 3xTgAD mice. A band corresponding to the IgG heavy
chain was detected and used as loading control. Densitometry quantiﬁcation
was done. n = 3, *p < 0.05, **p < 0.01.
control; p = 0.101) sites or total Tau (110.2 ± 9.7% vs con-
trol; p = 0.37) with Tau5 antibody in long-term control mice
(Figure 3D). In the long-term control mice, capacity of CDK5
to phosphorylate an in vitro substrate such as histone H1 has a
tendency to increase, but it was not signiﬁcant (151.6 ± 19.2% vs
control; p = 0.0726; Figure 3E).
SHORT-TERM EFFECTS OF CDK5 KNOCKDOWN – 3 WEEKS AFTER
DELIVERY
Animals were injected at 18 months of age and evaluated 3 weeks
later. Thus the animals in this experiment were sacriﬁced at the
same age as the long-term (1 year) treated animals described
above that were treated with shCDK5miR at 6 months. These
“short term” animals did not show alterations in the visible
test [session effect F(1,32) = 25.562; p < 0.001; treatment
effect F(1,32) = 3.246; p = 0.081; session-treatment effect
F(1,32) = 0.218; p = 0.644; Figure 4A, Visible platform].
Although the shCDK5miR group improved their performance
in the last hidden platform learning sessions [session 7 (Mann–
Whitney U test; p = 0.036] and session 8 [Mann–Whitney U test;
p = 0.017)], there was no session-treatment effect [session effect
F(7,224) = 7.562; p < 0.001; treatment effect F(1,32) = 1.291;
p = 0.264; session-treatment effect F(7,224) = 2.862; p = 0.007;
Figure 4A, Hidden platform]. Spatial memory analysis showed
a clear difference in the probe trial of the shCDK5miR group
compared to the shSCRmiR animals. This result was compara-
ble to the results in the LT-3xTg-AD performance. The latency
to ﬁnding the platform in the shCDK5miR group was lower
than in the shSCRmiR group (Mann–Whitney U test p = 0.015;
Figure 4A, Probe trial) and preference by the platform quad-
rant was also superior in the shCDK5miR treated mice as shown
by the time spent in the platform quadrant and path length
[two-way ANOVA F(1,32) = 6.863; p = 0.013; Figures 4B,C].
These ﬁndings suggest a short-term ameliorative effect on spatial
memory.
Tauopathy was signiﬁcantly diminished in the ST-3xTg-AD
with shCDK5miR injection. Sarkosyl-insoluble and soluble frac-
tions showed a reduction in hyperphosphorylated Tau after
3 weeks of treatment (Figure 5A). We conﬁrmed the reduction
of CDK5 protein levels 3 weeks after treatment (38.8 ± 12.2%
vs control; p = 0.006) and wide variation in AT8 (49.4 ± 28.3%
vs control; p = 0.108) and AT100 (42.5 ± 33.14% vs control;
p = 0.112) immunoreactivities that failed to achieve statisti-
cal signiﬁcance (Figure 5B). AT180 did not achieve statistical
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FIGURE 3 | Long-term treatment with CDK5 RNAi’s reduced
phosphorylatedTau in control animals (littermates with only the
PS1M146Vknock-in) but did not affect spatial memory. MorrisWater Maze
(MWM) testing was performed in 18-month-old control mice 1 year after
injection with shSCRmiR (white squares) and shCDK5miR (gray squares). (A)
Values of latency to reach the visible and hidden platform during training and
probe trial tests 48 h after training. (B)Time spent in the target quadrant and
(C) path plots for the median path length during the probe trial. (TQ = target
quadrant, RQ = right quadrant, UQ = upper quadrant and OQ = oppositive
quadrant.) Data are presented as mean ± SEM. n = 10 by each group.
*p < 0.05, **p < 0.01. (D) Steady-state levels of CDK5 and AT8 decreased
after injection of shCDK5miR in hippocampal lysates of aged littermate mice
injected with shSCRmiR (white bars) and shCDK5miR (gray bars). There was
no statistical signiﬁcance between shSCRmiR and shCDK5miR in AT100,
AT180, PHF1 andTau5 levels. Representative blots are shown. Tubulin was
used as loading control. Densitometry quantiﬁcation was done, RU = relative
units. n = 4. *p < 0.05, **p < 0.01. (E) CDK5 kinase activity evaluated by
histone phosphorylation in long-term treatment in control mice. A band
corresponding to the IgG heavy chain was detected and used as loading
control. Densitometry quantiﬁcation was done. n = 3, *p < 0.05, **p < 0.01.
FIGURE 4 | Short-term treatment with shCDK5miR induced recovery of
spatial memory. Deﬁcits in spatial learning were reduced in 3xTgAD mice
injected with shCDK5miR (gray square) in comparison with shSCRmiR
(white squares). (A) Values of latency to reach the visible and hidden
platform during training, and probe trial tests 48 h after training.
shCDK5miR injection improved the performance of 3xTgAD mice during
the training with the hidden platform and the probe trial. (B) Time spent in
the target quadrant and (C) path plots for the median path length that
evidenced the recovery in the preference by the platform position.
(TQ = target quadrant, RQ = right quadrant, UQ = upper quadrant and
OQ = oppositive quadrant.) Data are presented as mean ± SEM. n = 17
by each group. *p < 0.05, **p < 0.01.
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FIGURE 5 | CDK5 knockdown diminished aggregation of insolubleTau in
old 3xTg-AD mice. (A) Separation of sarkosyl-insoluble and soluble Tau
showed that shCDK5miR can decrease insoluble Tau evaluated with PHF1
antibody (64 kDa band) in a short-term treatment in 3xTgAD mice compared
to control. β-actin was used as loading control. (B) CDK5 protein levels
reduced in the CDK5 knockdown in 3xTgAD mice. AT8, AT100 and AT180
levels after injection of shCDK5miR did show any statistically signiﬁcant
decrease. Representative blots are shown. Tubulin was used as loading
control. Densitometry quantiﬁcation was done. n = 3, *p < 0.05, **p < 0.01.
(C) Quantiﬁcation of PHF1 evaluated by immunoﬂuorescence in CA1 revealed
that shCDK5miR decreased the intensity of ﬂuorescence in 3xTg-AD mice.
PHF1 in red (Alexa 594) and GFP in green. Magniﬁcation 60×. Scale bar,
50 μm; n = 3; *p < 0.05, **p < 0.01. Densitometry quantiﬁcation was done.
n = 3, *p < 0.05, **p < 0.01.
signiﬁcance, but did show a decreasing trend (36.2 ± 29% vs
control; p = 0.079; Figure 5B). As seen in both aged control
mice and ST-3xTg-AD, total Tau with Tau5 antibody did not dif-
fer between the groups (113.2 ± 31.9% vs control; p = 0.359;
Figure 5B). PHF1 immunoﬂuorescence was signiﬁcantly reduced
in CA1 [25.8 ± 11.39% (shCDK5miR) vs control; p = 0.02;
Figure 5C]. These studies support a short-term ameliorative effect
on Tau phosphorylation.
Control mice (PS1M146Vknock-in) at 18 months of age were
injected in CA1 with AAV containing shCDK5miR or shSCR-
miR. All mice were evaluated by the MWM test 3 weeks
post-injection. Performance with the visible platform demon-
strated no deﬁcits in visual, motor or motivational func-
tions in the injected animals [session effect F(2,40) = 53.747;
p < 0.001; treatment effect F(1,20) = 0.003; p = 0.958;
session-treatment effect F(2,40) = 0.285; p = 0.753; Figure 6A,
Visible platform]. Both shCDK5miR and shSCRmiR groups
learned the tasks in the hidden platform training [session effect
F(7,140) = 11.85; p < 0.001], and there were no differ-
ences in searching the location of the hidden platform [treat-
ment effect F(1,20) = 0.262; p = 0.614; session-treatment
effect F(7,140) = 0.768; p = 0.615; Figure 6A, Hidden plat-
form]. 48 h after the last learning trial was assessed a probe
trial (without platform), did not reveal any differences in the
latency in reaching the platform-demarcated area [t(20) = 0.23;
p = 0.982] or time spent in the target quadrant [two-way ANOVA
F(1,20) = 0.573; p = 0.458; Figure 6A (Probe trial), and
Figures 6B,C].
CDK5 was diminished in the hippocampi of aged control
shCDK5miR-treated animals in comparison to shSCRmiR-treated
animals (50.2 ± 14.6% vs control; p = 0.021; Figure 6D).
We immunoblotted Tau to evaluate its phosphorylation state at
the AT8, AT100, AT180, and PHF-1 epitopes. CDK5 silencing
reduced Tau phosphorylation at the AT8 (36.6 ± 21.8% vs con-
trol; p = 0.0311) and AT100 epitopes (32.2 ± 17.7% vs control;
p = 0.031), with a tendency toward a decrease at the AT180 epi-
tope (35.3 ± 23.7% vs control; p = 0.056); but not at the PHF1
(101.5 ± 18.3% vs control; p = 0.471). Total Tau with Tau5 was
unchanged in aged littermates (88.7± 44.1%vs control; p = 0.408;
Figure 6D).
DISCUSSION
The ﬁndings in this study demonstrate several novel beneﬁts of
CDK5 RNAi treatment. The ameliorative effects of the treatment
using anAAV delivery system persist for at least a year after a single
dose. Treatment can prevent the Tau pathology and the decline
in memory when given before symptoms occur. Also, treatment
reduced Tau pathology and induced a clear functional recovery in
affected old animals as measured by MWM testing. Those results
are consistent with reports of long-term efﬁcacy in mice (Boye
et al., 2011), nonhuman primates (Bankiewicz et al., 2006) and in
humans (Palﬁ et al., 2014).
The improvement in the 3xTg-AD mice both in terms of their
Tau pathology and their behavior, reinforces and extends several
reports on the beneﬁcial effects of clearing hyperphosphorylated
Tau (Alvarez et al., 1999; Zheng et al., 2002, 2005, 2010; Wang
et al., 2003; Zhang et al., 2004, 2013; Wen et al., 2007; Piedrahita
et al., 2010; Castro-Alvarez et al., 2011; Crews et al., 2011). Also,
a great deal of evidence supports the occurrence of behavioral
deﬁcits in 3xTg-AD mice (Oddo et al., 2003; Billings et al., 2005;
Clinton et al., 2007; Gulinello et al., 2009). We showed that aged
3xTg-AD mice easily found the visual platform, and therefore,
the animals can learn the task. However, they failed to reach the
hidden platform and failed in the probe trial. CDK5 knockdown
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FIGURE 6 | CDK5 RNAi’s reduced phosphorylatedTau in control animals
(littermates with only the PS1M146Vknock-in) but did not affect spatial
memory. Morris Water Maze (MWM) testing was performed in 18-month-old
control mice injected with shSCRmiR (white squares) and shCDK5miR (gray
squares). (A) Values of latency to reach the visible and hidden platform during
training and probe trial tests 48 h after training. (B)Time spent in the target
quadrant and (C) path plots for the median path length during the probe trial.
(TQ = target quadrant, RQ = right quadrant, UQ = upper quadrant and
OQ = opposite quadrant.) Data are presented as mean ± SEM. n = 10 by
each group. *p < 0.05. (D) Steady-state levels of CDK5, AT8 and AT100
decreased after injection of shCDK5miR in hippocampal lysates of aged
littermate mice injected with shSCRmiR (white bars) and shCDK5miR (gray
bars). There was no statistically signiﬁcant difference between shSCRmiR and
shCDK5miR in AT180, PHF1 andTau5 levels. Representative blots are shown.
Tubulin was used as a loading control. Densitometry quantiﬁcation was done.
RU = relative units. n = 4. *p < 0.05.
induced a functional recovery in aged 3xTg-AD at 1 year (long-
term) and 3 weeks (short-term) following delivery of the short
hairpin. These behavioral improvements were supported by a
signiﬁcant reduction of sarkosyl-insoluble Tau. Hyperphospho-
rylated Tau decreased in both treatment time-lines, in contrast
to CDK5 activity and p25 that decreased in the short-term treat-
ment arm (Piedrahita et al., 2010), suggesting some loss in CDK5
knockdown efﬁciency over the long term in old 3xTgAD and
control mice. Although, this long term silencing maybe pre-
vented the tau hyperphosphorylation in the animals before of
the disease began in the hippocampus, in spite of the damage
in surrounding brain areas continued, and those are connected
with the hippocampus. Also, other altered kinases are involved in
different phosphorylation sites of tau in AD (Augustinack et al.,
2002), affecting the reduction of CDK5 activity by shCDk5miR
in the hippocampus of 3xTgAD mice. In addition, in long term
treated old control mice the main prevention of phosphoryla-
tion of tau was on ser202, thr205 (AT-8), which has been related
with aging or PHF in PS1 KI mice (Kurt et al., 2003). Oppo-
sitely, CDK5 down-regulation was not enough to reverse all the
phosphorylation sites on tau in old 3xTgAD mice at 3 weeks
post-injection.
Tauopathy reduction linked to kinase inhibition has shown
behavioral recovery in different animals models. 3xTgAD and
transgenic p25 mice treated with diaminothiazoles can reduce
tauopathy and improve cognitive function by both CDK5 and
GSK3β inhibition (Zhang et al., 2013). These observations are
indirectly supported by the demonstration that the reduction of
p35 to p25 cleavage by calpain inhibition prevented cognitive alter-
ations in transgenic mouse models (Liang et al., 2010; Medeiros
et al., 2012). Furthermore, Crews et al. (2011) have shown res-
cue of neurogenesis alterations after pharmacological and genetic
inhibition of CDK5 in an APP transgenic mice.
On the other side, in our study CDK5 knockdown did not
affect old control mice at either long or short-term time points.
Main effect of inhibition or knock down of CDK5 on nonin-
jured mice improves relearning skill more than learning process
(Hawasli et al., 2007). Reversal learning has different electrophys-
iological implications and has been linked to the function of
the NR2B subunit of the NMDA receptor and AMPA receptor
(Dong et al., 2013). However, transfer test was not evaluated in
the present study. But could suggest that reducing CDK5 activity
can have positive effects on learning and memory independent of
its Tau effects, but in younger mice, as shown by Plattner et al.
(2014).
The search for therapeutic approaches to prevent or slow the
progression of AD is a very high priority. The tauopathy of AD
has been a particularly stubborn problem with few, if any, phar-
maceutical options. One obstacle to correcting the tauopathy is
the paucity of critical targets, which can serve as the basis for
future drug discovery. In conclusion, CDK5 knockdown as a treat-
ment and prevention appears to be a reasonable target based on
taupathology and behavioral effects in 3xTg-AD mice, and suggest
to be safety to the long term in both disease and control conditions,
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presenting the CDK5miR as a potential translation gene therapy.
However, the discovery of CDK5 small molecule inhibitors has
been challenging. These results should foster a search for deeper
insights into the mechanisms of CDK5 in brain homeostatic con-
trol, and improved delivery approaches for safe and long-lasting
vectors and ultimately systemic administration of small molecules
that can speciﬁcally and safely reduce CDK5 activity.
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